Pfizer Inc. $PFE Stake Reduced by KCM Investment Advisors LLC

KCM Investment Advisors LLC trimmed its holdings in Pfizer Inc. (NYSE:PFE) by 19.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 96,755 shares of the biopharmaceutical company’s stock after selling 22,891 shares during the quarter. KCM Investment Advisors LLC’s holdings in Pfizer were worth $2,465,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Winch Advisory Services LLC grew its position in Pfizer by 3.3% in the third quarter. Winch Advisory Services LLC now owns 18,080 shares of the biopharmaceutical company’s stock worth $461,000 after buying an additional 579 shares during the last quarter. Advisory Alpha LLC boosted its stake in shares of Pfizer by 10.8% during the 3rd quarter. Advisory Alpha LLC now owns 39,668 shares of the biopharmaceutical company’s stock worth $1,074,000 after acquiring an additional 3,882 shares in the last quarter. JT Stratford LLC grew its holdings in shares of Pfizer by 301.6% in the 3rd quarter. JT Stratford LLC now owns 70,370 shares of the biopharmaceutical company’s stock worth $1,793,000 after acquiring an additional 52,849 shares during the last quarter. Cambria Investment Management L.P. raised its position in shares of Pfizer by 14.6% during the third quarter. Cambria Investment Management L.P. now owns 421,336 shares of the biopharmaceutical company’s stock worth $10,280,000 after purchasing an additional 53,745 shares during the period. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Pfizer by 4.5% during the third quarter. Dimensional Fund Advisors LP now owns 36,335,531 shares of the biopharmaceutical company’s stock valued at $925,109,000 after purchasing an additional 1,579,117 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on PFE. Bank of America dropped their price target on Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a research note on Monday, December 15th. UBS Group assumed coverage on shares of Pfizer in a research report on Tuesday, January 6th. They issued a “neutral” rating and a $25.00 target price on the stock. Zacks Research upgraded shares of Pfizer from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 24th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research note on Thursday, January 22nd. Finally, Daiwa Securities Group downgraded shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 target price on the stock. in a research note on Thursday, February 12th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, fourteen have given a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, Pfizer has a consensus rating of “Hold” and an average target price of $28.05.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Federal judge approved a settlement awarding Pfizer $29 million related to the SEC’s 2013 insider‑trading case involving SAC Capital, closing a long‑running legal dispute and delivering a modest one‑time cash gain. Judge approves Pfizer, SEC settlement tied to insider trading at Cohen hedge fund
• Positive Sentiment: Argus Research upgraded PFE to Buy with a $35 target, highlighting encouraging progress in Pfizer’s GLP‑1 obesity program and its oncology pipeline — a bullish catalyst for longer‑term revenue growth expectations. Argus Turns Bullish on Pfizer (PFE), Highlights GLP-1 and Oncology Pipeline
• Positive Sentiment: Investor writeups note portfolio renewal progress and attractive dividend yield for patient investors, framing Pfizer as a value/dividend play while its pipeline rebuild continues. Pfizer’s Portfolio Renewal In Progress – High Yields For The Patient
• Neutral Sentiment: Some outlets note the stock is down modestly since the last earnings release and are asking whether it can rebound — a monitoring signal rather than fresh news. Pfizer (PFE) Down 0.6% Since Last Earnings Report: Can It Rebound?
• Neutral Sentiment: Telescope Innovations installed a second self‑driving lab at Pfizer — a partnership update that points to operational/automation improvements but is unlikely to move near‑term revenues. Telescope Innovations Installs Second Self-Driving Lab at Pfizer
• Neutral Sentiment: Valuation pieces note divergence between long‑term return expectations and DCF views, signaling mixed investor opinions on fair value and outlook. A Look At Pfizer (PFE) Valuation As Long Term Returns And DCF Views Diverge
• Negative Sentiment: Analysis highlights structural growth challenges — falling COVID revenues, upcoming patent expirations and pricing/IRA headwinds — that could pressure sales and margins if new launches don’t scale. Can Pfizer Reignite Growth Amid COVID Declines and Patent Expirations?
• Negative Sentiment: Opinion pieces warn of “obesity hype” and potential vaccine policy shocks that could create volatility around expectations for new GLP‑1 products and vaccine revenues. Pfizer: Obesity Hype And Vaccine Policy Shocks

Pfizer Stock Performance

Shares of PFE opened at $26.63 on Friday. The company has a market capitalization of $151.43 billion, a PE ratio of 19.58 and a beta of 0.47. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16. The company’s 50 day moving average price is $26.26 and its 200 day moving average price is $25.46. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $27.94.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. The company had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The company’s revenue was down 1.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.63 EPS. Research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.5%. The ex-dividend date is Friday, January 23rd. Pfizer’s payout ratio is currently 126.47%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.